| [1] |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7):783-791.
|
| [2] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1):17-48.
|
| [3] |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
|
| [4] |
von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703.
|
| [5] |
O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase Ⅱ trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation[J]. J Clin Oncol, 2020, 38(13):1378-1388.
|
| [6] |
Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 402(10409):1272-1281.
|
| [7] |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.
|
| [8] |
Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388(1):33-43.
|
| [9] |
Luchini C, Brosens LAA, Wood LD, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications[J]. Gut, 2021, 70(1):148-156.
|
| [10] |
Zong Y, Yuan J, Peng Z, et al. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study[J]. J Cancer Res Clin Oncol, 2021, 147(5):1529-1536.
|
| [11] |
Giommoni E, Maiello E, Vaccaro V, et al. Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study)[J]. Curr Oncol, 2021, 28(3):1761-1772.
|
| [12] |
Assenat E, de la Fouchardière C, Portales F, et al. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ⅰb-Ⅱ controlled clinical trial[J]. ESMO Open, 2021, 6(6):100318.
|
| [13] |
Pokataev I, Fedyanin M, Polyanskaya E, et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies[J]. ESMO Open, 2020, 5(1):e000578.
|
| [14] |
Kondo T, Kanai M, Matsubara J, et al. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study[J]. Med Oncol, 2023, 40(5):144.
|
| [15] |
Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. Science, 2008, 321(5897):1801-1806.
|
| [16] |
Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes[J]. Nature, 2012, 491(7424):399-405.
|
| [17] |
Luo J. KRAS mutation in pancreatic cancer[J]. Semin Oncol, 2021, 48(1):10-18.
|
| [18] |
Hallin J, Bowcut V, Calinisan A, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor[J]. Nat Med, 2022, 28(10):2171-2182.
|
| [19] |
Qin S, Li J, Bai Y, et al. Nimotuzumab plus gemcitabine for K-ras wild-type locally advanced or metastatic pancreatic cancer[J]. J Clin Oncol, 2023, 41(33):5163-5173.
|
| [20] |
Goodwin CM, Waters AM, Klomp JE, et al. Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer[J]. Cancer Res, 2023, 83(1):141-157.
|
| [21] |
Qiang L, Hoffman MT, Ali LR, et al. Transforming growth factor-β blockade in pancreatic cancer enhances sensitivity to combination chemotherapy[J]. Gastroenterology, 2023, 165(4):874-890, e10.
|
| [22] |
Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ⅰb/Ⅱ study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(36):4284-4292.
|
| [23] |
De Jesus-Acosta A, Sugar EA, O'Dwyer PJ, et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma[J]. Br J Cancer, 2020, 122(4):498-505.
|
| [24] |
van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase Ⅲtrial of pegvorhyaluronidase Alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma[J]. J Clin Oncol, 2020, 38(27):3185-3194.
|
| [25] |
Tong M, Wang J, Zhang H, et al. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase Ⅲtrials[J]. J Cancer, 2019, 10(4):968-978.
|
| [26] |
Gore J, Korc M. Pancreatic cancer stroma: friend or foe?[J]. Cancer Cell, 2014, 25(6):711-712.
|
| [27] |
Zhang Z, Ji S, Hu Q, et al. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer[J]. Clin Transl Med, 2021, 11(8):e398.
|
| [28] |
Philip PA, Azar I, Xiu J, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma[J]. Clin Cancer Res, 2022, 28(12):2704-2714.
|
| [29] |
Padrón LJ, Maurer DM, O'Hara MH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J]. Nat Med, 2022, 28(6):1167-1177.
|
| [30] |
Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6):1189-1198.
|
| [31] |
Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer[J]. N Engl J Med, 2022, 386(22):2112-2119.
|
| [32] |
Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618(7963):144-150.
|
| [33] |
杨尹默, 李宝毅, 马永蔌. 胰腺癌免疫治疗现状与进展[J]. 中华普通外科杂志, 2023, 38(5):321-325.
|